Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $670,800.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the sale, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at $9,180,820.35. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00.
• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Price Performance

PCVX stock traded down $2.49 on Friday, reaching $79.98. 755,075 shares of the company were exchanged, compared to its average volume of 1,069,661. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The stock's fifty day moving average price is $85.77 and its 200 day moving average price is $94.57. The firm has a market capitalization of $9.97 billion, a PE ratio of -17.39 and a beta of 0.98.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on PCVX shares. Needham & Company LLC reissued a "buy" rating and issued a $14.00 price objective on shares of Vaxcyte in a research note on Tuesday, February 11th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $127.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Whipplewood Advisors LLC bought a new position in Vaxcyte during the fourth quarter valued at about $28,000. Blue Trust Inc. lifted its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the period. Smartleaf Asset Management LLC boosted its stake in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares in the last quarter. National Bank of Canada FI bought a new stake in Vaxcyte in the 4th quarter valued at $41,000. Finally, Meeder Asset Management Inc. raised its stake in shares of Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after buying an additional 635 shares in the last quarter. Institutional investors own 96.78% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.